Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
HRS9531 in Atherosclerotic Cardiovascular Disease (ASCVD)
NCT07551492Phase 3Recruiting
- Sponsor
- Fujian Shengdi Pharmaceuticals
- Start
- May 2026
- Primary completion
- May 2031
- Modality
- Peptides, Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in atherosclerotic cardiovascular disease (ASCVD) comparing HRS9531 Group A with HRS9531 placebo Group B (2 arms). Primary endpoint: Major Adverse Cardiovascular Events 3 up to 61 months. Started May 2026; status: recruiting.
02
Drugs
HRS9531
03
Conditions
atherosclerotic cardiovascular disease (ASCVD)
Beyond the preview
Go deeper on NCT07551492.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07551492.